BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

561 related articles for article (PubMed ID: 12699451)

  • 1. Giant prolactinomas in men: efficacy of cabergoline treatment.
    Corsello SM; Ubertini G; Altomare M; Lovicu RM; Migneco MG; Rota CA; Colosimo C
    Clin Endocrinol (Oxf); 2003 May; 58(5):662-70. PubMed ID: 12699451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas.
    Di Sarno A; Landi ML; Marzullo P; Di Somma C; Pivonello R; Cerbone G; Lombardi G; Colao A
    Clin Endocrinol (Oxf); 2000 Jul; 53(1):53-60. PubMed ID: 10931080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage.
    Colao A; Di Sarno A; Landi ML; Cirillo S; Sarnacchiaro F; Facciolli G; Pivonello R; Cataldi M; Merola B; Annunziato L; Lombardi G
    J Clin Endocrinol Metab; 1997 Nov; 82(11):3574-9. PubMed ID: 9360509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of macroprolactinoma with cabergoline: a study of 85 patients.
    Ferrari CI; Abs R; Bevan JS; Brabant G; Ciccarelli E; Motta T; Mucci M; Muratori M; Musatti L; Verbessem G; Scanlon MF
    Clin Endocrinol (Oxf); 1997 Apr; 46(4):409-13. PubMed ID: 9196602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of long-term cabergoline treatment for giant prolactinoma: study of 12 men.
    Shimon I; Benbassat C; Hadani M
    Eur J Endocrinol; 2007 Feb; 156(2):225-31. PubMed ID: 17287412
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cabergoline as a first-line treatment in newly diagnosed macroprolactinomas.
    Pontikides N; Krassas GE; Nikopoulou E; Kaltsas T
    Pituitary; 2000 May; 2(4):277-81. PubMed ID: 11081149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cabergoline: a first-choice treatment in patients with previously untreated prolactin-secreting pituitary adenoma.
    Cannavò S; Curtò L; Squadrito S; Almoto B; Vieni A; Trimarchi F
    J Endocrinol Invest; 1999 May; 22(5):354-9. PubMed ID: 10401709
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients.
    Colao A; Di Sarno A; Landi ML; Scavuzzo F; Cappabianca P; Pivonello R; Volpe R; Di Salle F; Cirillo S; Annunziato L; Lombardi G
    J Clin Endocrinol Metab; 2000 Jun; 85(6):2247-52. PubMed ID: 10852458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment.
    Colao A; Di Sarno A; Sarnacchiaro F; Ferone D; Di Renzo G; Merola B; Annunziato L; Lombardi G
    J Clin Endocrinol Metab; 1997 Mar; 82(3):876-83. PubMed ID: 9062500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The assessment of cabergoline efficacy and tolerability in patients with pituitary prolactinoma type.
    Bolko P; Jaskuła M; Waśko R; Wołuń M; Sowiński J
    Pol Arch Med Wewn; 2003 May; 109(5):489-95. PubMed ID: 14768178
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hormone levels and tumour size response to quinagolide and cabergoline in patients with prolactin-secreting and clinically non-functioning pituitary adenomas: predictive value of pituitary scintigraphy with 123I-methoxybenzamide.
    Colao A; Ferone D; Lastoria S; Cerbone G; Di Sarno A; Di Somma C; Lucci R; Lombardi G
    Clin Endocrinol (Oxf); 2000 Apr; 52(4):437-45. PubMed ID: 10762286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Giant prolactinomas larger than 60 mm in size: a cohort of massive and aggressive prolactin-secreting pituitary adenomas.
    Shimon I; Sosa E; Mendoza V; Greenman Y; Tirosh A; Espinosa E; Popovic V; Glezer A; Bronstein MD; Mercado M
    Pituitary; 2016 Aug; 19(4):429-36. PubMed ID: 27138902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dopamine agonist for the rapid improvement of visual field defects in giant and macro-prolactinomas.
    Hacisahinogullari H; Canturk S; Dogansen S; Yarman S
    J Fr Ophtalmol; 2022 May; 45(5):511-518. PubMed ID: 35272874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term efficacy of bromocriptine in macroprolactinomas and giant prolactinomas in men.
    Chattopadhyay A; Bhansali A; Masoodi SR
    Pituitary; 2005; 8(2):147-54. PubMed ID: 16379032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Giant prolactinoma presented as unilateral exophthalmos in a prepubertal boy: response to cabergoline.
    Krassas GE; Pontikides N; Kaltsas T
    Horm Res; 1999; 52(1):45-8. PubMed ID: 10640900
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prolactinomas resistant to standard doses of cabergoline: a multicenter study of 92 patients.
    Vroonen L; Jaffrain-Rea ML; Petrossians P; Tamagno G; Chanson P; Vilar L; Borson-Chazot F; Naves LA; Brue T; Gatta B; Delemer B; Ciccarelli E; Beck-Peccoz P; Caron P; Daly AF; Beckers A
    Eur J Endocrinol; 2012 Nov; 167(5):651-62. PubMed ID: 22918301
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of parasellar extension of macroprolactinomas defined by magnetic resonance imaging on their responsiveness to dopamine agonist therapy.
    Delgrange E; Duprez T; Maiter D
    Clin Endocrinol (Oxf); 2006 Apr; 64(4):456-62. PubMed ID: 16584520
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluaton of therapy with cabergoline in men with macroprolactinoa.
    Andrysiak-Mamos E; Kaźmierczyk-Puchalska A; Zochowska E; Sowińska-Przepiera E; Sagan L; Kojder I; Syrenicz A
    Pomeranian J Life Sci; 2015; 61(3):263-9. PubMed ID: 27344867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resistant prolactinomas: a case series of 26 patients.
    Eshkoli T; Fraenkel M; Zaid D; Cohen D; Yoel U; Tsvetov G; Gorshtein A; Goldbart A; Greenman Y; Shimon I
    Endocrine; 2022 Aug; 77(2):349-356. PubMed ID: 35604631
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of resistance to the prolactin-lowering effects of cabergoline in macroprolactinomas: a study in 122 patients.
    Delgrange E; Daems T; Verhelst J; Abs R; Maiter D
    Eur J Endocrinol; 2009 May; 160(5):747-52. PubMed ID: 19223454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.